Insider · CIK 0001198330
Guy P Nohra
Files at TELA (TELA Bio, Inc.), BVS (Bioventus Inc.). First filing Dec 8, 2025, latest Dec 8, 2025.
Guy P Nohra files SEC Form 4 as director at BVS (Bioventus Inc.), and also at TELA (TELA Bio, Inc.). Since Dec 8, 2025, Guy P Nohra has reported 0 open-market buys worth $0 and 1 open-market sell worth $76k, the latest filed on Dec 8, 2025.
A track record needs three past buys with six months of prices behind them; Guy P Nohra has 0, so none is measured yet.
The newest scored trade: sold $76k of BVS on Dec 4, 2025, filed Dec 8, 2025, scored 23 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $76k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BVS: Bioventus Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | BVSsell Bioventus Inc. | $76k 10,000 shares | -8% | +24% from low-35% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 4, 2025 | BVS Bioventus Inc. | 10,000 0.01% of outstanding | $76k | Dec 4, 2025 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | TELA TELA Bio, Inc. | AGrant or award Common Stock | +11,925 | $0.00 | $0 | 11,925 | Jun 11, 2026 |
| Jun 9, 2026 | TELA TELA Bio, Inc. | AGrant or award Common Stock | +11,675 | $0.00 | $0 | 23,600 | Jun 11, 2026 |
| Jun 9, 2026 | TELA TELA Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,550 | $0.00 | $0 | 17,550 | Jun 11, 2026 |
| Jun 9, 2026 | TELA TELA Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,335 | $0.00 | $0 | 17,335 | Jun 11, 2026 |
| Jun 2, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +32,282 | $0.00 | $0 | 148,892 | Jun 4, 2026 |
| Jun 2, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -32,282 | $0.00 | $0 | 0 | Jun 4, 2026 |
| Jun 3, 2026 | BVS Bioventus Inc. | AGrant or award Restricted Stock Unitsderivative | +25,146 | $0.00 | $0 | 25,146 | Jun 4, 2026 |
| Dec 4, 2025 | BVS Bioventus Inc. | SOpen-market sale Class A Common Stock | -10,000 | $7.57 | $76k | 116,610 | Dec 8, 2025 |
| Jun 2, 2025 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +26,493 | $0.00 | $0 | 126,610 | Jun 4, 2025 |
| Jun 2, 2025 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -26,493 | $0.00 | $0 | 0 | Jun 4, 2025 |
| Jun 3, 2025 | BVS Bioventus Inc. | AGrant or award Restricted Stock Unitsderivative | +32,282 | $0.00 | $0 | 32,282 | Jun 4, 2025 |
Questions about Guy P Nohra
Answered from the filings on this page, as of the latest one.
Is Guy P Nohra buying or selling?
In the last 12 months Guy P Nohra reported 0 open-market buys worth $0 and 1 open-market sell worth $76k on SEC Form 4; the latest was sold $76k of BVS on Dec 4, 2025. Grants, option exercises and tax withholding are not counted.
How did Guy P Nohra's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Guy P Nohra has 0.
Where does Guy P Nohra file Form 4?
Guy P Nohra has filed Form 4 at BVS (Bioventus Inc.); TELA (TELA Bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.